IL-21 in cancer immunotherapy.

Authors :: Santegoets, Saskia J. A. M.
Turksma, Annelies W.
Powell Jr., Daniel J.
Hooijberg, Erik
de Gruijl, Tanja D.
Source :: OncoImmunology; Jun2013, Vol. 2 Issue 6, pe24522-1-e24522-3, 3p
Publication Year :: 2013
Abstract: Interleukin-21 (IL-21) has been described as a potent stimulator of antitumor T-cell immunity, but also of autoimmune reactions and oncogenesis. Antigen presenting cells genetically modified to release IL-21 allow for the expansion of tumor-specific T cells exhibiting favorable effector and growth characteristics and a minimal risk of detrimental side effects. [ABSTRACT FROM AUTHOR]